In recent years, ASK1 has emerged as a therapeutic target for fibrotic diseases, with ASK1 inhibitors in phase-III clinical trials for chronic kidney disease and nonalcoholic steatohepatitis.16,17 Here, we show that ASK1 inhibitors, such as selonsertib, have potential therapeutic value in hypertensive heart disease, reducing cardiac fibrosis together with cardiomyocyte hypertrophy (Figure 6). The gene discussed is MAP3K5; the disease is hypertensive heart disease.